Related references
Note: Only part of the references are listed.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA
Johannes Kettunen et al.
NATURE COMMUNICATIONS (2016)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Net Reclassification Improvement: Computation, Interpretation, and Controversies
Maarten J. G. Leening et al.
ANNALS OF INTERNAL MEDICINE (2014)
BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries
Tanja Zeller et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a) Prospective 15-Year Outcomes in the Bruneck Study
Peter Willeit et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2012)
Combining individual participant and aggregated data in a meta-analysis with correlational studies
Terri Pigott et al.
RESEARCH SYNTHESIS METHODS (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
EUROPEAN HEART JOURNAL (2012)
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2011)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Management of Lp(a)
W. Virgil Brown et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Lipoprotein(a) levels and risk of future coronary heart disease
Anna Bennet et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population
Pia R. Kamstrup et al.
CIRCULATION (2008)
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease
S Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inference on correlated discrimination measures in survival analysis: A nonparametric approach
L Antolini et al.
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS (2004)
Lp(a) lipoprotein, vascular disease, and mortality in the elderly
AA Ariyo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein (a).: Population-based reference values in an area with low incidence of cardiovascular disease
JM Simó et al.
CLINICAL BIOCHEMISTRY (2003)
Adjusting for multiple testing - when and how?
R Bender et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)
Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly - The SENECA study
JH Contois et al.
CLINICA CHIMICA ACTA (2000)
Share Paper
